Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18) PET/CT Scan

− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in…

Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18) PET/CT Scan

− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in men…

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming ASTRO Annual Meeting

BURLINGTON, Mass. and OXFORD, UK, September 10, 2019 – Blue Earth Diagnostics, a Bracco company…

Bracco Imaging announces completion of acquisition of Blue Earth Diagnostics

Oxford (UK), August 1st, 2019 - Bracco Imaging today announced that it has completed the…

Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging

‒ Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management…

Blue Earth Diagnostics Announces Results from Investigational Clinical Study of Safety and Effectiveness of 18F-Fluciclovine PET Imaging in Adult Glioma

─ Presented at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting ─  …

Blue Earth Diagnostics Announces Results from Investigational Clinical Study of Safety and Effectiveness of 18F-Fluciclovine PET Imaging in Adult Glioma

─ Presented at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting ─  …

Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) in Europe

Oxford, UK – May 9, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…